What is Paradromics?
Paradromics is pioneering advanced brain-computer interface (BCI) technology designed to restore communication and independence for individuals suffering from severe paralysis due to conditions such as ALS, stroke, and spinal cord injuries. The company's flagship product, Connexus, is engineered to enable non-verbal individuals to communicate through digital interfaces, while its secondary focus, Tempo, explores mental health brain-state monitoring. By integrating high-resolution neural data with sophisticated AI algorithms, Paradromics translates complex brain activity into actionable health insights. This dual-pronged approach addresses both the immediate needs of the paralyzed community and the broader, growing demand for scalable neurotechnology solutions in mental health and neurological diagnostics.
How much funding has Paradromics raised?
Paradromics has raised a total of $61.3M across 5 funding rounds:
Debt
$985K
Angel/Seed
$7M
Debt
$350K
Angel/Seed
$20M
Other Financing Round
$33M
Debt (2015): $985K, investors not publicly disclosed
Angel/Seed (2018): $7M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Angel/Seed (2021): $20M featuring Dolby Family Ventures, Alpha Edison, Synergy Ventures, Pureland Group, Prime Movers Lab, Westcott, and IT Farm
Other Financing Round (2023): $33M backed by Green Sands Equity, Westcott, and Dolby Family Ventures
Key Investors in Paradromics
Dolby Family Ventures
An investment firm focused on supporting early-stage companies that address significant science and engineering challenges, particularly in the biotech and pharmaceutical sectors.
Green Sands Equity
A boutique private equity firm specializing in growth equity investments across technology and healthcare, with a global footprint and advisory services for government policy.
Westcott Investment Group
A Dallas-based family investment office that manages diverse platforms and provides financial services tailored to optimize wealth management and strategic growth.
What's next for Paradromics?
With the recent influx of capital, Paradromics is well-positioned to accelerate the clinical validation and commercialization of its BCI hardware. The strategic focus will likely shift toward refining the Connexus platform for broader clinical adoption and expanding the research capabilities of the Tempo system. As the company navigates the complex regulatory landscape of medical devices, the support from its diverse investor base—ranging from family offices to specialized biotech venture firms—will be instrumental in navigating international market entry and scaling manufacturing processes. The firm remains committed to its long-term vision of providing durable, high-fidelity neurotechnology that addresses the most challenging unmet medical needs in the global healthcare market.
See full Paradromics company page
